The effect of age, parity and body mass index on the efficacy, safety, placement and user satisfaction associated with two low-dose levonorgestrel intrauterine contraceptive systems: Subgroup analyses of data from a phase III trial

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Gemzell Danielsson, Kristina ^a   Apter, Dan ^b   Hauck, Brian ^c   Schmelter, Thomas ^d   Rybowski, Sarah ^e   Rosen, Kimberly ^e   Nelson, Anita ^f  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Vaestoliitto   (Finland)

^c UNIVERSITY OF CALGARY   (Canada)

^d BAYER PHARMA AG   (Germany)

^e BAYER CORPORATION   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVONORGESTREL; CONTRACEPTIVE AGENT;

ADULT; AGE; ARTICLE; BODY MASS; CESAREAN SECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ECTOPIC PREGNANCY; FEMALE; HIGH RISK POPULATION; HUMAN; INCIDENCE; LOW DRUG DOSE; MENSTRUAL CYCLE; NULLIPARA; OUTCOME ASSESSMENT; PARITY; PATIENT SATISFACTION; PELVIC INFLAMMATORY DISEASE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; VAGINAL DELIVERY; YOUNG ADULT; ADOLESCENT; ADVERSE EFFECTS; CLINICAL TRIAL; CONSUMER ATTITUDE; DOSE RESPONSE; INTRAUTERINE CONTRACEPTIVE DEVICE; PAIN; PREGNANCY; SAFETY; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ADULT; AGE FACTORS; BODY MASS INDEX; CONSUMER BEHAVIOR; CONTRACEPTIVE AGENTS, FEMALE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; PAIN; PARITY; PREGNANCY; SAFETY; YOUNG ADULT;

EID: 84945575652     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135309     Document Type: Article

References (16)

1. Lyus R, Lohr P, Prager S (2010) Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. Contraception 81: 367-371. doi: 10.1016/j.contraception.2010.01.010 PMID: 20399942
2. World Health Organization (2010) Medical eligibility criteria for contraceptive use: fourth edition. Available: http://whqlibdoc.who.int/publications/2010/9789241563888-eng.pdf. Accessed 11 May 2015.
3. Centers for Disease Control and Prevention (2010) MMWR: Sexually transmitted diseases treatment guidelines 2010. Available: http://www.cdc.gov/std/treatment/2010/pid.htm. Accessed 21 October 2014.
4. Faculty of the Royal College of Obstetricians and Gynaecologists (2009) UK medical eligibility for contraceptive use. Available: http://www.fsrh.org/pdfs/UKMEC2009.pdf. Accessed 27 July 2015.
5. Tyler CP, Whiteman MK, Zapata LB, Curtis KM, Hillis SD, Marchbanks PA (2012) Health care provider attitudes and practices related to intrauterine devices for nulliparous women. Obstet Gynecol 119: 762-771. doi: 10.1097/AOG.0b013e31824aca39 PMID: 22433340
6. Gemzell-Danielsson K, Schellschmidt I, Apter D (2012) A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril 97: 616-622. doi: 10.1016/j.fertnstert.2011.12.003 PMID: 22222193
7. Nelson AL, Apter D, Hauck B, Schmelter T, Rybowski S, Rosen K et al. (2013) Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol 122: 1205-1213. doi: 10.1097/AOG.0000000000000019 PMID: 24240244
8. Bayer Health Care Pharmaceuticals Inc. (2012) Cost of unintended pregnancy: model technical report-UK.
9. Bayer HealthCare Pharmaceuticals Inc (2013) Skyla® Prescribing Information.
10. Black K, Lotke P, Buhling KJ, Zite NB (2012) A review of barriers and myths preventing the more widespread use of intrauterine contraception in nulliparous women. Eur J Contracept Reprod Health Care 17: 340-350. doi: 10.3109/13625187.2012.700744 PMID: 22834648
11. Gemzell-Danielsson K, Mansour D, Fiala C, Kaunitz AM, Bahamondes L (2013) Management of pain associated with the insertion of intrauterine contraceptives. Hum Reprod Update 19: 419-427. doi: 10.1093/humupd/dmt022 PMID: 23670222
12. Bahamondes MV, Hidalgo MM, Bahamondes L, Monteiro I (2011) Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas. Contraception 84: e11-e16. doi: 10.1016/j.contraception.2011.05.012 PMID: 22018132
13. Prager S, Darney PD (2007) The levonorgestrel intrauterine system in nulliparous women. Contraception 75: S12-S15. PMID: 17531602
14. Veldhuis HM, Vos AG, Lagro-Janssen AL (2004) Complications of the intrauterine device in nulliparous and parous women. Eur J Gen Pract 10: 82-87. PMID: 15534571
15. Madden T (2010) Rates of continuation and expulsion of intrauterine contraception at 12 months in nulliparous and adolescent women. Contraception 82: 187-188.
16. Larimore WL, Stanford JB (2000) Ectopic pregnancy with oral contraceptive use has been overlooked. BMJ 321: 450.